Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Alexander Hanzl, Ryan Casement, Hana Imrichová, et al.
Nature Chemical Biology (2022) Vol. 19, Iss. 3, pp. 323-333
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 116
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 76
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Vladas Oleinikovas, Pablo Gaínza, Thomas Ryckmans, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 291-312
Open Access | Times Cited: 51
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Martin Schröder, Martin Renatus, Xiaoyou Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 37
Induced protein degradation for therapeutics: past, present, and future
Hojong Yoon, Justine C. Rutter, Yen-Der Li, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 1
Open Access | Times Cited: 21
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
Alexander Hanzl, Eleonora Barone, Sophie Bauer, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 2, pp. 1176-1184
Open Access | Times Cited: 31
The rise of degrader drugs
Mingxing Teng, Nathanael S. Gray
Cell chemical biology (2023) Vol. 30, Iss. 8, pp. 864-878
Open Access | Times Cited: 27
Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
Gang Xue, Jianing Xie, Matthias Hinterndorfer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 7
Mechanism of degrader-targeted protein ubiquitinability
Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
Structural Basis of Conformational Dynamics in the PROTAC‐Induced Protein Degradation
Hongtao Zhao
ChemMedChem (2024) Vol. 19, Iss. 14
Open Access | Times Cited: 7
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Chrysanthi Kagiou, José A. Cisneros, Jakob Farnung, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Miquel Duran‐Frigola, Marko Cigler, Georg E. Winter
Journal of the American Chemical Society (2023) Vol. 145, Iss. 5, pp. 2711-2732
Open Access | Times Cited: 20
Base editor screens for in situ mutational scanning at scale
Nicholas Z. Lue, Brian B. Liau
Molecular Cell (2023) Vol. 83, Iss. 13, pp. 2167-2187
Open Access | Times Cited: 18
Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2
Sarath Ramachandran, Nikolai Makukhin, Kevin Haubrich, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Thomas Geiger, Michael Walz, Christian Meyners, et al.
Angewandte Chemie International Edition (2023) Vol. 63, Iss. 3
Open Access | Times Cited: 16
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 15
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Yufeng Xiao, Yaxia Yuan, Yi Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 6
The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells
Gernot Wolf, Conner Craigon, Shao Thing Teoh, et al.
Cell chemical biology (2025)
Open Access
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders
Yanqing Zhang, Wenjing Liu, Chao Tong, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Implications of frequent hitter E3 ligases in targeted protein degradation screens
Xiaoyu Zhang, Gabriel M. Simon, Benjamin F. Cravatt
Nature Chemical Biology (2025)
Closed Access
Identification of actionable targeted protein degradation effector sites through Site-specific Ligand Incorporation-induced Proximity (SLIP)
Zhangping Xiao, Efthymios Spyridon Gavriil, Fangyuan Cao, et al.
(2025)
Open Access
Workflow for E3 Ligase Ligand Validation for PROTAC Development
Nebojša Miletić, Janik Weckesser, Thorsten Mosler, et al.
ACS Chemical Biology (2025)
Open Access
Small molecule targeted protein degradation via the UPS: venturing beyond E3 substrate receptors
Renyu Guo, Fukang Yang, Emily C. Cherney
RSC Medicinal Chemistry (2025)
Closed Access
Page 1 - Next Page

Scroll to top